You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Autonomous Broad Spectrum Environmental Sentinels

    SBC: NEVADA NANOTECH SYSTEMS, INC.            Topic: A13AT017

    We propose a platform for aerial environmental monitoring based on the integration of two advanced technologies for the first time: a lightweight, flying robotic platform capable of hovering and swarming, and a compact, low-power chemical sensor platform called the Molecular Property Spectrometer (MPS): a robust, low-cost, silicon-chip-based micro-electro-mechanical system (MEMS) that has been use ...

    STTR Phase I 2014 Department of DefenseArmy
  2. Robust Terrain-Adaptive Vehicle Planning and Control

    SBC: Quantum Signal LLC            Topic: A14AT018

    Autonomous or teleoperated navigation of unmanned ground vehicles (UGVs) is difficult even in benign environments due to challenges associated with perception, decision making, and human-machine interaction, among others. In environments with rough, sloped, slippery, and/or deformable terrain, the difficulty of the navigation problem increases dramatically. In this effort, Quantum Signal, LLC, Un ...

    STTR Phase I 2014 Department of DefenseArmy
  3. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel

    SBC: ProDevice Medical Supplies and Equipment LLC            Topic: NCI

    Project Abstract Active surveillance (AS) is becoming more accepted as a reasonable treatment option for men with low-risk prostate cancer (i.e. Gleason score 6, clinical stage T2a, PSA lt 10). Many AS protocols at major institutions call for a prostate saturation biopsy after initial diagnosis to confirm that the patient has no areas of higher-risk prostate cancer. For most patients who underwent ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel scFv-Antibody Fusion siRNA Carrier Protein for Macroglobulinemia Treatment

    SBC: SIRNAX, Inc.            Topic: NCI

    This goal of this project is to develop an innovative process for treating patients with Waldenstr m's macroglobulinemia by suppressing the production of IgM. Waldenstr m's macroglobulinemia is incurable and fatal. The manifestations of this disease that are due to high concentrations of monoclonal IgM are hyperviscosity with headache, fatigue, impaired cognition, confusion, and stroke, ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Neuroprotective Agent For Cerebral Palsy Prevention

    SBC: Zietchick Research Institute, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Cerebral palsy (CP), the most common physical disability in childhood, afflicts more than 800,000 Americans and many more worldwide. In addition to motor difficulties, many children with CP also suffer from intellectualdisability, epilepsy, nutritional problems, and language dysfunction. Furthermore, almost 90% of CP-associated brain injuries occur in utero or ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government